Steve Pakola - Jan 1, 2022 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Chief Medical Officer
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Jan 1, 2022
Transactions value $
-$91,603
Form type
4
Date filed
1/4/2022, 08:05 PM
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Tax liability -$37.7K -1.15K -10.47% $32.70 9.85K Jan 1, 2022 Direct
transaction RGNX Common Stock Sale -$53.9K -1.6K -16.23% $33.75 8.25K Jan 3, 2022 Direct F1, F2
transaction RGNX Common Stock Award $0 +8.9K +107.88% $0.00 17.2K Jan 3, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Stock Option (Right to Buy) Award $0 +42.5K $0.00 42.5K Jan 3, 2022 Common Stock 42.5K $34.31 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $33.72 to $33.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer.
F4 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer.